This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Contemporary Use of Neuromuscular Blockade in Complex Patients: Maximizing Safety and Effectiveness

Contemporary Use of Neuromuscular Blockade in Complex Patients: Maximizing Safety and Effectiveness


Slide Lecture Series

Time to Complete

1.50 hours


May 25, 2018


May 25, 2019
Add to Queue

Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Pharmacy Credits

Pharmacists may earn 1.50 CPE Credits (0.15 CEUs) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck

Program Description

Critically ill patients may receive neuromuscular blocking agents (NMBAs) as adjunctive therapy in acute respiratory distress syndrome, shivering management, or for selected procedures; however, the use is less frequent than in the past. In addition, post-operative patients may experience residual blockade upon direct admission to the surgical intensive care unit (ICU). Awareness of the risks and management of NMBAs is important for ICU practitioners. Many aspects of patient management during continuous paralysis were addressed in the 2016 Society of Critical Care Medicine (SCCM) Guidelines for Sustained Neuromuscular Blockade; however, the use of a reversal agent was not included. This symposium will review the guidelines and discuss the role of NMBA reversal.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in critical care and postoperative settings.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Review key clinical practice statements from the 2016 Society of Critical Care Medicine (SCCM) Clinical Practice Guidelines for Sustained Neuromuscular Blockade in Critically Ill Adults.
  • Apply the guidelines in patient case scenarios examining commonly administered neuromuscular blocking agents, their purpose, and potential side effects.
  • Discuss strategies to minimize patient risk from residual neuromuscular blockade.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.


Judith Jacobi, PharmD, BCCCP, DPNAP, FCCP, MCCM, Activity Chair
Critical Care Pharmacy Specialist
Indiana University Health Methodist Hospital
Indianapolis, Indiana

Dr. Jacobi has nothing to disclose.

Sean A. Nix, DO, FACOS
Director of Trauma
Saint Luke’s Hospital
Kansas City, Missouri

Dr. Nix has nothing to disclose.

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


In order to receive credit, participants must complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue